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Abstract
Imbalances in the synthesis or in the bioavailability of nitric oxide (NO), the freely dif‐
fusible vasodilator, in myocardial endothelial cells were demonstrated to be crucial in 
the development of hypertension. Glucocorticoids (GCs) are widely used as immuno‐
modulators. One of the numerous side effects of GC therapy is hypertension arising from 
reduced release of the endothelium‐derived NO. GCs can modulate NO synthesis by 
targeting the genes involved in it, like nitric oxide synthase (NOS) and guanosine tri‐
phosphate (GTP) cyclohydrolase‐1 (GTPCH‐1). This chapter will give an overview on 
the impact of GCs on NO synthesis and signalling in animal models as well as in in vitro 
cell culture models. Moreover, strategies for preventing or neutralizing side effects of 
long‐term GC therapy will be discussed.
Keywords: myocardial endothelial cells, nitric oxide, nitric oxide synthase, 
glucocorticoids, glucocorticoid receptor
1. Introduction
Hypertension mediated by glucocorticoids (GCs) is a frequent clinical problem. Among oth‐
ers it results from the fact that GCs remain as one of the most commonly prescribed drugs for 
many conditions, such as inflammatory diseases, asthma, multiple sclerosis, chronic obstruc‐
tive pulmonary disease (COPD) and many more. Either the pharmacological administration 
of GCs or intrinsic GC excess in humans (caused that is by Cushing syndrome) may result in 
hypertension. The problem was originally discussed to originate from sodium excess or from 
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an impairment of water reabsorption by the renal mineralocorticoid receptor [1, 2]. However, 
extensive experimental and clinical data begun to unravel the complex molecular mecha‐
nisms inducing the onset and leading to a persistence of pathologically high blood pressure 
induced by GCs. In addition, recent research pointed to the role of extra‐renal tissues, such 
as the vascular endothelium, that have not been taken into account so far in the regulation of 
blood pressure. The importance of glucocorticoid receptor (GR) signalling became more and 
more obvious in this process [3, 4].
Effects of GCs on vessel vasodilatation and nitric oxide (NO) synthesis as well as imbal‐
ances between NO and superoxide were examined extensively in numerous in vitro and 
in vivo studies. Imbalances in the bioavailability of endothelium‐derived NO play a cru‐
cial role in diverse cardiovascular diseases including hypertension, arteriosclerosis and 
hypercholesterolemia [5–11]. NO is also known to influence circulating platelets and white 
blood cells and modulates various cellular events, such as platelet activation, mitochon‐
drial function, ion transport, inflammation, angiogenesis and cell proliferation, all pro‐
cesses being essential in cardiovascular homeostasis. It also contributes to the control of 
the heart rate and its contractility. Although its role in these processes is not fully known, 
the amount of bioactive NO has been suggested to be involved in the control of cardiac 
contractility. While lower NO levels seem to promote contractility, higher levels have the 
opposite effects [12]. It limits cardiac remodelling after ischemic injury. NO is known to be 
constitutively generated in cardiomyocytes by two different NO synthase (NOS) isoforms, 
the endothelial and neuronal one indicating different roles of these isoforms in cardiac 
function [13]. In this chapter, we summarized the state of knowledge from available experi‐
mental data considering the influence of externally administered GCs on the synthesis of 
the vasodilatator NO in hypertension. Hypertension arising from intrinsic GC excess will 
not be discussed here.
2. Glucocorticoids and the glucocorticoid receptor
GCs are steroid hormones synthesized in the adrenal glands. They are essential for life and 
involved in various cellular processes, such as in the regulation of metabolic and immunologi‐
cal pathways, and the control of cellular homeostasis. Cortisol is the main form of GCs pro‐
duced in the human body. Multiple naturally occurring as well as synthetic compounds, like 
dexamethasone, are being used in the treatment of diverse inflammatory and immunological 
diseases. The cellular effects mediated by GCs, including genomic and non‐genomic ones, are 
exerted by binding to their receptor, the GR. In its inactive state, the GR is kept in the cytosol 
fraction by chaperon proteins, such as the heat shock protein 90 (HSP90). The lipophilic GCs 
diffuse through the cell membrane into the cytosol; they bind to the GR which in that moment 
is released by the HSPs and is then activated (Figure 1). After dimerization, the GR‐GC com‐
plex enters the nucleus where it binds to so‐called glucocorticoid response elements (GREs) 
located in the promoter regions of target genes. By this binding, the GR activates or represses 
the expression of its specific targets [14]. Moreover, by binding to other transcription factors, 
the GR can indirectly influence the expression of certain other genes [14].
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The GR is conserved among all species and its expression was confirmed in a wide range of 
tissues including the vascular endothelium. It was also shown to be expressed in microvas‐
cular endothelial cells of the myocardium and of the blood‐brain barrier [15–19]. The protein 
amount of the GR correlates with its transcriptional activity. Under physiological conditions, 
the GC turnover and the recycling process of receptor/transcriptional DNA complexes is 
regulated by the 26S proteasome as well as by the degradation of the GR (Figure 1) [20, 21].
Although GCs are the most widely prescribed medicine, systemic GC administration, especially 
for a long period, is associated with numerous detrimental side effects [22, 23]. GC‐induced 
Figure 1. Glucocorticoid receptor signalling. In its inactive state, the glucocorticoid receptor (GR) is kept in the cytosol 
by chaperon proteins, such as the heat shock protein 90 (HSP90). The lipophilic GCs diffuse through the cell membrane 
into the cytosol, bind to the GR resulting in release of GR from the HSP complex and its activation. After dimerization, 
the GR‐GC complex enters the nucleus where it binds to so‐called glucocorticoid response elements (GREs) located in 
the promoter regions of target genes. The protein amount of the GR correlates with its transcriptional activity. Under 
physiological conditions and excess GC treatment, the recycling process of receptor/transcriptional DNA complexes is 
regulated by the 26S proteasome, GR ubiquitination and degradation.
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hypertension is one of the common undesirable effects. Tissue‐specific GR knockout mice shed 
light on the molecular mechanisms behind GC‐induced hypertension. Against expectations, 
a GR deletion in the distal nephron did not protect mice against hypertension caused by GC 
administration [24]. Also, the lack of GR in vascular smooth muscle cells has only delayed the 
onset of hypertension in comparison to wild‐type mice [25]. Finally, mice with a tissue‐spe‐
cific GR knockout in the vascular endothelium were resistant to GC‐induced hypertension 
[26]. These facts underlined the pivotal role of the GR expressed in vascular endothelial cells 
in generation and maintenance of GC‐mediated hypertension demonstrating that cell‐specific 
actions of the GR are responsible for the phenotype of a whole organism.
3. Glucocorticoid effects on the NO synthesis and signalling pathway
3.1. Influence on eNOS
At cellular level, GCs negatively influence the synthesis of NO causing endothelial dys‐
function. NOS is expressed in three isoforms: neuronal NOS (nNOS, NOS1), inducible 
NOS (iNOS, NOS2) and endothelial NOS (eNOS, NOS3) [27, 28]. Under physiological cir‐
cumstances, all NOS isoforms can catalyse the conversion of l‐arginine to l‐citrulline and 
NO. Endothelial NOS constitutively produces NO in vascular endothelial cells. Cofactors 
involved in this process, such as 5,6,7,8,‐tetrahydrobiopterin (BH
4
), are limiting elements 
in the synthesis of NO. It has been observed that the absence of BH
4
 or l‐arginin leads to 
eNOS uncoupling and to the production of reactive oxygen species (ROS) instead of NO. 
In consequence, this results in endothelial dysfunction followed by severe vascular disor‐
ders, that is, of cardiovascular nature [29]. The pivotal role of eNOS and its product NO in 
regulating the blood pressure and blood flow was demonstrated in eNOS knockout and 
eNOS over‐expressing mice. While mice lacking eNOS were hypertensive, animals over‐
expressing eNOS in the vascular tissue became hypotensive and suffered from decreased 
vasoreactivity [30–32]. These mice models confirmed that blood pressure is regulated by 
eNOS‐derived NO. Therefore, first efforts to explain the molecular mechanism of GC‐
mediated hypertension focussed on the regulation of eNOS.
GCs lead to a down‐regulation of eNOS mRNA and protein in cultured endothelial cells, 
in the aorta and in organs such as kidney and liver of GC‐treated rats [33]. In vivo, disrup‐
tion of the eNOS gene preserved mice from hypertension [34]. In vitro studies with human 
umbilical vein endothelial cells(HUVECs) have demonstrated that endogenous GR acts as a 
negative regulator of both eNOS and iNOS. It was shown that a GR knockdown in HUVECs 
increased eNOS mRNA and protein levels [35]. An endothelial deletion of the GR in mice 
resulted in an accelerated expression of eNOS in septic mice [35]. Moreover, other animal 
studies demonstrated that following GC treatment, the expression of eNOS was significantly 
down‐regulated [33, 36]. The observed eNOS reduction could be further confirmed at pro‐
moter level after identification of a potential GRE in the promoter region of this gene [37]. 
This study which has been performed in HUVECs demonstrated the suppression of the eNOS 
promoter activity in response to cortisol application. In line with these results, the binding of 
the GR to the suppressive GRE at −111 to −105 bp located on the NOS promoter was tested 
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by  chromatin  immunoprecipitation [37]. Recently, a dexamethasone‐mediated regulation 
of the eNOS promoter in microvascular myocardial endothelial cells derived from mice has 
been shown. Concordantly with previous results, a GC‐mediated suppression of the eNOS 
promoter could be measured [19]. The GR can inhibit eNOS and other forms of NOS by 
trans‐repressive interactions with other transcription factors, such as NFκB or AP‐1 [38, 39]. 
Moreover, recent reports revealed the meaning of the molar ratio between BH
4
 and eNOS 
rather than the absolute amounts of the cofactor and its enzyme. As we know by now, GCs 
cause a reduction of both BH
4
 and eNOS. They also inhibit NOS phosphorylation without an 
evident uncoupling of eNOS after GCs treatment [40].
3.2. Effects on l‐arginine and BH
4
GCs are known to alter various molecules in the NOS‐mediated biosynthesis of NO. l‐arginine 
is an essential substrate for all NOS isoforms. In GC‐induced hypertension, systemic levels 
of l‐arginine and l‐citrulline have been observed to be diminished reflecting the importance 
of upstream NOS regulators in this clinical condition [41]. l‐arginine supplementation could 
partially reverse hypertension in GC‐treated rats [41, 42]. BH
4
 is an essential cofactor of eNOS 
in the biosynthesis of NO [43]. It can be produced by two different strategies. The first is via 
the conversion from GTP catalysed by the GTP cyclohydrolase 1 (GTPCH‐1), which is the 
rate‐limiting enzyme involved in its synthesis. The second way is the salvage production path‐
way, where the precursor protein sepiapterin is converted into the intermediate molecule BH
2
 
and then into BH
4
 [44]. The importance of the bioavailability of BH
4
 was validated in ex vivo 





‐free preparations could be determined [45, 46]. Limited amounts of BH
4
 can lead 
to an uncoupling of eNOS and further to endothelial dysfunction [47, 48]. Uncoupled eNOS 









 can be reconverted to BH
4
 by dihydrofolate reductase (DHFR) [53]. A GC 
supplementation of cultured human endothelial cells was shown to reduce mRNA and protein 
levels of DHFR [40]. Furthermore, administration of external BH
4
 led to an increase of NO 
levels following GC‐treatment, as it was demonstrated in animal studies as well as in coronal 
endothelial cells [51, 54]. However, BH
4
 application or treatment with sepiapterin, a precursor 
of BH
4
, did not alter systolic blood pressure although total concentrations of plasma BH
4
 were 
elevated in GC‐induced hypertensive rats [55, 56]. GC effects on BH
4
 and NO down‐regulation 
have been proven to be genomic by the usage of specific GR antagonists. One of such antago‐
nistic compounds is RU486, the application of which could reverse the decreasing effects on 
NO synthesis caused by GC treatment [34, 57].
3.3. Control of GTP cyclohydrolase 1
As the rate‐limiting enzyme involved in the de novo biosynthesis of BH
4
, GTPCH‐1 shows 
a decreased expression in response to GC treatment. As a result of its decrease, a signifi‐
cantly lowered BH
4
 and NO production contributed to impaired endothelium‐dependent 
vaso‐relaxation [55, 58, 59]. In vitro studies with human and mouse endothelial cells demon‐
strated genomic effects of GCs on GTPCH‐1 by GC‐mediated down‐regulation of GTPCH‐1 
mRNA and promoter activity [19, 40]. It was also shown that dexamethasone mediated a 
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dense down‐regulation of both GTPCH‐1 and eNOS after a long‐term treatment period [19]. 
Elsewhere it was shown that a gene transfer of human GTPCH‐1 restored vascular BH
4
 con‐
centrations and positively influenced endothelial function in hypertonic rats [60]. The sum‐
mary of this data clearly displays that GCs influence the whole multistep cascade of NO 
production mediated by eNOS.
4. Strategies to reduce glucocorticoid‐induced hypertension
Since mechanisms behind GC‐induced side reactions, such as hypertension, are complex 
and in part controversial, a basic knowledge of the pharmacology, clinical guidelines and 
the adverse effects of these substances is imperative. Once increased blood pressure as an 
unwanted effect of GC treatment has been detected, the use of appropriate anti‐hypertensive 
compounds, such as NO‐generating compounds and direct vasodilators and hybrid drugs 
possessing a NO‐releasing moiety including diuretics, calcium channel blockers, angiotensin‐
converting enzyme (ACE) inhibitors, angiotensin receptor blockers, β‐blockers, α‐adrenergic 
receptor antagonists, centrally acting α‐2 receptor agonists, should be considered. There are 
different strategies and natural as well as synthetic compounds that have been discussed to 
reduce or prevent GC‐induced imbalances occurring in the production of NO. A brief over‐
view on the most important ones that directly influence NO availability or signalling will be 
given below.
4.1. Reducing glucocorticoid toxicity
First of all, the side effects of a drug administration should be considered in terms of the drug 
duration/dosage, which in turn should take into account the risk/benefit ratio. GC‐induced 
side effects are usually more severe following systemic than topical application. As an impor‐
tant parameter, a definite indication to start GC treatment should be considered. Moreover, 
short‐ and intermediate‐acting ones should be preferred over longer‐acting GCs and a mini‐
mum necessary dose and duration of treatment should be chosen. Furthermore, a once‐a‐day 
morning administration should be preferred over a divided dose therapy. Necessarily, the 
body weight, blood and ocular pressure, the development of cataracts, serum lipids, blood 
and urine glucose concentration should be monitored during the complete GC therapy.
4.2. NO‐generating agents
Several drugs act as NO‐releasing agents. Well known are organic nitrates and nitrites, includ‐
ing nitroglycerin acting as anti‐anginal drug. However, the use of these agents has been asso‐
ciated with some limitations and some of the compounds are still tested in clinical trials.
Pulmonary rather than cardiac hypertension can be reduced by a direct delivery of NO into 
the lung though inhalation. Reaching well‐ventilated areas of the lungs, inhaled NO increases 
blood oxygenation and improves ventilation‐perfusion. However, its effect on the systemic 
arterial tone is minor since NO is rapidly scavenged and acutely inactivated after reacting 
with circulating haemoglobin [61]. Therefore, effects of distal NO rather occur due to the 
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formation of other bioactive nitrogen oxides, including inorganic nitrate and S‐nitrosothiols 
acting in an endocrine manner [62].
Nitrite therapy also contributes to the regulation of blood flow and blood pressure through 
its reduction to NO catalysed by metalloprotein oxidoreductases. The bioconversion of nitrite 
into NO in the vascular system is regulated by a reductive reaction with deoxyhaemoglobin 
and couples hypoxic sensing with NO production and therefore augmented under physi‐
ological or pathological hypoxia [63–65]. Inhaled nitrite causes pulmonary vasodilatation and 
induces protective remodelling in animal studies [66]. Moreover, nitrite reduces blood pres‐
sure and improves cell and organ viability after ischemia reoxygenation as it was shown in 
the heart, liver and lungs [67, 68]. Either oral or inhaled delivery of nitrite has been shown to 
exhibit a rapid and efficient systemic absorption and is still tested for further effects in various 
clinical studies.
Nitrate can be considered as a pro‐drug that is further metabolized to nitrite and other nitro‐
gen oxides after application. Due to its long half‐life, the enterosalivary circulation and ref‐
ormation, nitrite ensures a low‐grade NO‐like bioactivity over a longer period of time [69]. 
Nitrate has been shown to possess a robust NO‐like activity in the cardiovascular system 
and can be assimilated from nitrate‐rich diet, especially in green leafy vegetables, or as a salt 
[70]. Animal models revealed compensating effects of dietary nitrite and nitrate on the lack of 
eNOS expression [71]. Similar to nitrite, nitrate has also cardio‐ and vascular‐ and renoprotec‐
tive properties and both molecules act as a blood pressure‐lowering and anti‐inflammatory 
agent in different animal models of cardiovascular diseases [72–74].
Regulatory functions for the cardiovascular system have also been demonstrated for nitrated 
fatty acids [75]. These electrophilic compounds can be generated in the reaction of unsatu‐
rated fatty acids with NO‐derived reactive species and act via NO‐dependent and NO‐inde‐
pendent pathways [76]. Besides positive effects on vascular relaxation, nitrated fatty acids 
have shown anti‐oxidative and anti‐inflammatory effects in blood vessels [77, 78]. Despite the 
cardio‐protective action of nitrated fatty acids proven in animal models, the first human clini‐
cal trial is still ongoing and safety is being tested.
4.3. l‐arginine and l‐citrulline administration
A direct and very simple way to enhance NO availability is l‐arginine delivery. As a sub‐
strate for all NOSs, this amino acid is present in sufficiently high concentrations in most 
cells. However, l‐arginine administration was observed to even increase NO generation [79]. 
Dietary l‐arginine possesses protective effects on the cardiac vascularity, as it was shown 
in a number of studies and is therefore frequently supplemented in food. However, mixed 
results of l‐arginine supplementation have been shown in multiple clinical trials, that is, no 
significant effects of l‐arginine on NO availability and on various cardiovascular parameters 
followed by even detrimental effects, such as a higher incidence of myocardial infarction after 
l‐arginine administration, were shown in clinical trials [80]. However, studies focusing on 
effects on blood pressure have shown blood pressure‐lowering effects [81]. The partially con‐
verse effects may partly result from the unspecific binding of this amino acid to all three NOS 
isoforms. Moreover, the molecule mediates many other effects than those associated with 
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NO metabolism, that is, it is a precursor of other amino acids or is a substrate for arginase, 
a key enzyme in the urea cycle [82]. In this context, it was identified that l‐arginine also 
interacts with the asymmetric dimethylarginine (ADMA) that acts as an endogenous NOS 
inhibitor. Since high ADMA levels are generated in cardiovascular diseases, l‐arginine sup‐
plementation seems to normalize but not improve NO levels and endothelial function in such 
 individuals [83].
A problem arising from l‐arginine administration might also be that this amino acid is exten‐
sively metabolized by intestinal bacteria and arginase in the liver before reaching the circula‐
tion [84]. Compared with l‐arginine, l‐citrulline has been shown to be effectively transported 
into endothelial cells where it is enzymatically converted into l‐arginine [84]. However, 
despite potential advantages shown for this molecule, no clinical trial has been initiated to 






 is an important factor controlling the activity of all NOS isoforms. Concerning the sal‐
vage pathway by which this factor can be produced endogenously, the external supplementa‐
tion of BH
4
 has been considered as a strategy improving NO synthesis and reducing eNOS 
uncoupling. Intracellular levels of BH
4
 can be restored by exposing cells to sepiapterin, being 
converted to BH
4
 through sepiapterin reductase. Satisfying results on superoxide formation 
and vascular function have been achieved by the administration of sepiapterin in various 
models of hypertension, that is, in spontaneously hypertensive or nephrectomised animals 
[85, 86]. Endothelial dysfunction has also been restored by sepiapterin in dexamethasone‐
incubated aorta rings ex vivo [55]. There are also in vitro studies applying aortic endothelial 
cells showing an improvement of NO release and decrease of ROS production [58]. There is 
one main difference between a direct BH
4
 and a sepiapterin administration. While sepiapterin 
is absorbed by cells and converted to intracellular BH
4
, a direct BH
4
 administration acts extra‐
cellularly [43]. Despite this seemingly important difference, there is only one report describ‐
ing sepiapterin administration, whereas a direct BH
4
 administration has not been described 
in the context of GC‐induced hypertension [56]. The low number of experimental data might 
be due to the fact that sepiapterin did not affect dexamethasone‐mediated hypertension in 
rats although plasma levels of BH
4
 were significantly increased. As the authors explained, 
the uncoupling of eNOS seems not to play a major role in the pathogenesis of GC‐induced 
hypertension [56].
4.5. Response to antioxidants and anti‐inflammatory agents
Antioxidants and anti‐inflammatory agents such as tempol, apocynin, N‐acetylcysteine, folic 
acid and atorvastatin can prevent and partially reverse GCs‐induced hypertension in vivo [87–
92]. Therefore, these substances represent promising candidates for prevention and treatment 
of increased systolic blood pressure induced by long‐term and high‐dosage GC treatment.
Tempol, 4‐hydroxy‐2,2,6,6‐tetramethyl piperidinoxyl, is a superoxide scavenger with either 
water‐soluble or membrane‐permeable characteristics. It is known to normalize blood  pressure, 
as it was shown in numerous animal models of differently induced hypertension [90, 93–95]. 
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Interesting findings have been reported by Zhang et al. They showed that tempol did not have 
an influence on oxidative stress measured in rat plasma. However, they reported tempol to 
have prevented and partially reversed dexamethasone‐induced hypertension independently 
of systemic ROS.
The hydrophilic antioxidant N‐acetylcysteine is already widely used in the clinic, that is, 
as a mucolytic agent or in ischemia‐reperfusion injury [96, 97]. In dexamethasone‐induced 
hypertension among rats, this agent was shown to lower systolic blood pressure as well as 
restore plasma NO levels, without any effect on oxidative markers in the plasma. Similar 
experimental settings revealed N‐acetylcysteine treatment having partially preventing but 
not reversing properties on GC‐induced hypertension in comparison to what has been 
shown for tempol [91].
The same laboratory tested folic acid in hypertension induced by synthetic GCs [87]. Folic acid 
is a B group vitamin that is known from its ROS decreasing properties [98]. It also lowers the 
concentration of homocysteine that reduces intracellular BH
4
 levels, thereby increasing BH
4
 
bioavailability [99]. Patients suffering from Cushing syndrome tend to have higher systemic 
homocysteine and reduced folate levels than healthy controls [100]. It is therefore not surprising 
that the supplementation of folic acid might prevent and partially revers GC‐induced hyper‐
tension by increasing BH
4
 amounts, although the detailed mechanism remains elusive [87].
The same group has demonstrated that antioxidant apocynin, which is a specific NAD(P)H 
oxidase inhibitor, is able either to reverse or to prevent dexamethasone‐caused hypertension 
[101]. Interestingly, the same study has shown that the NO precursor l‐arginine did not have 
the same effects as those being observed for apocynin in dexamethasone‐induced hyperten‐
sive rats.
Among its pleiotropic functions, atorvastatin has been reported to improve endothelial func‐
tion through increased bioavailability of NO and ameliorated ROS and pro‐inflammatory 
cytokine production in different models of hypertension [92, 102, 103]. Atorvastatin could 
lower the blood pressure of dexamethasone‐treated hypertensive rats due to its positive influ‐
ence on the expression of eNOS measured in aortic samples and due to the lowered levels of 
superoxide in plasma. However, there was no significant effect of this compound on vaso‐
relaxation although the endothelial function was markedly improved [92].
4.6. Influencing the GC signalling pathway
As it was shown in a transgenic animal model, an endothelial GR knockout was protected 
against GC‐induced hypertension [26]. Targeting GR in endothelial cells could therefore con‐
stitute a preventive treatment strategy directed against GC‐induced hypertension. A recent 
study by Blecharz et al. provided new insights into the GC‐mediated disturbances of NO 
production in the mouse microvascular endothelial cell line MyEND [19]. They observed 
negative effects on NO‐synthesis either after a short treatment period of 24 and 48 h or after a 
long‐term GC administration persisting 30 days. These effects were accompanied by lowered 
NO concentrations and eNOS activity in response to dexamethasone application. However, 
instead of reduced eNOS protein expression, a decrease of GTPCH‐1 protein they  documented 
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a decrease of GTPCH‐1 protein. Interestingly, the observed changes in enzymes and cofactors 
involved in NO synthesis were accompanied by a significantly lowered immune reactivity 
of the GR in MyEND cells. Ligand‐dependent down‐regulation of the GR, associated with 
the loss of functional GC responsiveness, was referred in numerous publications [20, 21, 104, 
105]. It was also shown that the expression of the GR is lower in endothelial cells derived from 
the mouse myocardium than in those isolated from the blood‐brain barrier [106]. Although 
the degradation of the receptor by the proteasome can be observed in capillaries from both 
organs, brain endothelial cells remain responsive to GCs due to a sufficient expression of 
the GR [17]. The complete loss of GC responsiveness verified in MyEND cells in contrast to 
endothelium of the central nervous system hinders the translocation of the GC‐GR complex 
into the nucleus, thereby hindering the transactivation of the GC target gene GTPCH‐1 (as 
depicted in Figure 1) [19]. As it was shown, blocking the proteasomal GR degradation by 
calpain inhibitor I or by over‐expressing a nondegradable GR isoform rescued either NO or 
BH
4
 levels, as well as eNOS activity in MyEND cells after GC treatment. Hence, these data 
provide the biochemical evidence that GC‐induced disturbed vasodilatation may result from 
the involvement of the proteasome in the failure of GC responsiveness rather than from GC‐
mediated trans‐repression of NO‐synthesizing molecules, as it was thought before [19, 57]. 
On the other hand, together with data gained in brain endothelial cells, the results support 
the endocrine heterogeneity of different vascular beds and a blockage of the proteasomal sig‐
nalling pathway may be a potential future option for neutralizing or reducing unfavourable 
effects of long‐term GC therapy [17, 107].
5. Conclusions
GC‐induced hypertension remains a severe clinical problem, since GCs are the widest pre‐
scribed drugs by clinicians. Despite numerous basic and clinical studies, the complexity of the 
induction and persistence of hypertension remains not entirely understood. A robust explana‐
tion for GC hypertension is that GCs reduce the activity and expression of eNOS. Moreover, 
enzymes and cofactors upstream of eNOS are negatively influenced. The effects mediated 
by GCs on these molecules can be genomic or non‐genomic. Therefore, further examinations 
are necessary to learn about this very frequent and serious clinical issue. On one hand, a 
detailed comprehension of the multistep GC/GR signalling cascade in the vasculature as well 
as in other non‐renal tissues is required. Moreover, the regulation of molecules upstream and 
downstream of eNOS by GCs in a genomic and non‐genomic manner should be clarified, 
given the fact that these effects might differ depending on the tissue. This might be explained 
by the evidence that the expression of the GR differs in a tissue‐specific manner. In addition, it 
will be necessary to develop new in vivo models mimicking this complex disease and helping 
to understand the interplay between organs such as the kidney, the liver, the cardiovascu‐
lar and the central nervous system. These animal models should be supported by single‐ or 
multi‐ tissue culture models in vitro. They would accelerate and promote the development of 
new compounds, such as synthetic and natural antioxidants lowering GC‐induced pathologi‐
cally increased blood pressure, and enable the identification of potential therapeutic targets.
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